FDA panel recommends Tysabri as Crohn's treatment
An FDA advisory panel voted 12-3 in favor of recommending Biogen IDEC and Elan's Tysabri for use in Crohn's disease patients, based on the drugs performance in clinical trials.
Your Email Address:
Recipient(s) Email Address:
(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)
Include a message (optional):
The e-mail address(es) that you supply to use this service will only be used to send the requested article.